MedTrace Logo

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

NCT02644486 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-10-02

No results posted yet for this study

Summary

To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.

Conditions

  • Obesity and Glomerulopathy

Interventions

DRUG

High dosage Sevelamer Carbonate + Irbesartan

Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d

DRUG

Low dosage Sevelamer Carbonate + Irbesartan

Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d

DRUG

Irbesartan

Irbesartan 300mg/d

Sponsors & Collaborators

  • Zhi-Hong Liu, M.D.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02644486 on ClinicalTrials.gov